Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 Operating Margin % is 28.98% as of Jun. 2026, which is 43% above its 10-year median of 20.28. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 815 Medical Devices & Instruments companies, LeMaitre Vascular ranks better than 94.72% on this metric.
LeMaitre Vascular Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for LeMaitre Vascular's Operating Margin % or its related term are showing as below:
LMAT'
s Operating Margin % Range Over the Past 10 Years
Min: 18.07 Med: 20.28 Max: 29.46
Current: 29.46
LMAT's Operating Margin % is ranked better than 94.72% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 3.29
vs LMAT: 29.46
LeMaitre Vascular's 5-Year Average Operating Margin % Growth Rate was 3.30% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
LeMaitre Vascular Operating Margin % Related Terms
LeMaitre Vascular Operating Margin % Historical Data
* Premium members only.
The historical data trend for LeMaitre Vascular's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LMAT vs PLSE, XRAY, ATRC: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's Operating Margin % distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
LeMaitre Vascular's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a Operating Margin % of 28.98% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on LeMaitre Vascular and its competitors. This is 43% above median its historical median of 20.28. Over the past decade, LeMaitre Vascular's Operating Margin % has ranged from 18.07 to 29.46. According to the industry distribution chart, LeMaitre Vascular ranks #43 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 5.3%.
Is LeMaitre Vascular's Operating Margin % too high?
LeMaitre Vascular's current Operating Margin % of 28.98% is 43% above median its 10-year median of 20.28. Over the past 10 years, this metric has ranged from a low of 18.07 to a high of 29.46. The Medical Devices & Instruments industry median Operating Margin % is 3.29. LeMaitre Vascular's value of 28.98% is 780.9% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #43 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's Operating Margin % compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #43 out of 815 companies for Operating Margin %. This places LeMaitre Vascular in the top 5% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.29. LeMaitre Vascular's value of 28.98% is 780.9% above this benchmark. Historically, LeMaitre Vascular's own Operating Margin % has ranged from 18.07 to 29.46 over the past decade. While the company's 10-year median is 20.28 vs. the industry median of 3.29, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.29, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current Operating Margin % of 28.98% is 780.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current Operating Margin % is 28.98%, which is 43% above median its own 10-year median of 20.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current Operating Margin % is 28.98%, which is 43% above median its 10-year median of 20.28 and 780.9% above the Medical Devices & Instruments industry median of 3.29. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current Operating Margin % is 28.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
Operating Margin %: 28.98% (43% above median its 10-year median of 20.28)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 780.9% above the Medical Devices & Instruments median (#43 of 815)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
